Intermittent Calcitriol Therapy and Growth in Children with Chronic Renal Failure

Intermittent calcitriol (1,25D) therapy has been used for the management of secondary hyperparathyroidism in children with chronic renal failure; however, the development of adynamic bone has been demonstrated in up to 40% of pediatric patients after 12 months of intermittent 1,25D therapy. To assess its effect on linear growth, we compared growth and biochemical data from 16 prepubertal patients with biopsy-proven secondary hyperparathyroidism during 12 months of intermittent 1,25D therapy and the preceding year of daily 1,25D therapy. While Z-scores for height remained stable during daily therapy, values decreased from –1.8 ± 0.32 to –2.0 ± 0.33, p < 0.01, during intermittent 1,25D therapy; the largest reductions were seen in those who developed adynamic bone. Reductions in growth may be due to the direct inhibitory effects of large intermittent doses of calcitriol on chondrocyte activity.

[1]  H. Jüppner,et al.  Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. , 1998, Kidney international.

[2]  B. Tönshoff,et al.  Reduced Concentration of Serum Growth Hormone (GH)-Binding Protein in Children with Chronic Renal Failure: Correlation with GH Insensitivity , 1997 .

[3]  B. Lanske,et al.  Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. , 1996, Endocrinology.

[4]  Aníbal Ferreira,et al.  PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats , 1996 .

[5]  Clifford J. Tabin,et al.  Regulation of Rate of Cartilage Differentiation by Indian Hedgehog and PTH-Related Protein , 1996, Science.

[6]  B. Lanske,et al.  PTH/PTHrP Receptor in Early Development and Indian Hedgehog--Regulated Bone Growth , 1996, Science.

[7]  H. Trachtman,et al.  Growth in children with moderate renal insufficiency: measurement, evaluation, and treatment. , 1996, The Journal of pediatrics.

[8]  A. Abou-Samra,et al.  Downregulation of the PTH/PTHrP receptor by vitamin D3 in the osteoblast-like ROS 17/2.8 cells. , 1996, The American journal of physiology.

[9]  T. Tsuboyama,et al.  1α,25‐dihydroxyvitamin D3 inhibits cell growth and chondrogenesis of a clonal mouse EC cell line, ATDC5 , 1996 .

[10]  P. Ureña,et al.  PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  W. Goodman,et al.  Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. , 1995, Kidney international.

[12]  G. Segre,et al.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. , 1994, Kidney international.

[13]  V. Chinchilli,et al.  A prospective double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol , 1994 .

[14]  B. Lacour,et al.  The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. , 1994, Kidney international.

[15]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.

[16]  G. Saggese,et al.  In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast‐like cells , 1993, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[17]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[18]  D. Stablein,et al.  Maintenance dialysis in North American children and adolescents: a preliminary report. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). , 1993, Kidney international. Supplement.

[19]  C. Farquharson,et al.  In vivo effect of 1,25‐dihydroxycholecalciferol on the proliferation and differentiation of avian chondrocytes , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  E. Ritz,et al.  Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients. , 1993, Clinical nephrology.

[21]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[22]  R. Fine.  Stimulating growth in uremic children. , 1992, Kidney international.

[23]  H. Ballal,et al.  Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  S. Mohan,et al.  1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. , 1991, Endocrinology.

[25]  Keith C. Norris,et al.  Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. , 1989, The New England journal of medicine.

[26]  D. Carnes,et al.  The effects of vitamin D metabolites on the plasma and matrix vesicle membranes of growth and resting cartilage cells in vitro. , 1988, Endocrinology.

[27]  W. Goodman,et al.  Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. , 1988, Kidney international.

[28]  A. Lindahl,et al.  Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. , 1987, Endocrine reviews.

[29]  W. Goodman,et al.  "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. , 1987, Kidney international.

[30]  J. Delmez,et al.  The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. , 1987, Kidney international.

[31]  J. Silver,et al.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. , 1986, The Journal of clinical investigation.

[32]  S. Alexander,et al.  Nutritional requirements for infants with renal failure. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  J. Russell,et al.  Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Brocklebank.  End Stage Renal Disease in Children , 1985 .

[35]  H. Harter,et al.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.

[36]  O. Isaksson,et al.  Growth hormone stimulates the proliferation of cultured chondrocytes from rabbit ear and rat rib growth cartilage , 1983, Nature.

[37]  H. DeLuca,et al.  Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. , 1978, The New England journal of medicine.

[38]  P. Betts,et al.  Growth Pattern and Dietary Intake of Children with Chronic Renal Insufficiency , 1974, British medical journal.

[39]  G. Stickler,et al.  A Review: Short Stature in Renal Disease , 1973, Pediatric Research.